Pertuzumab Biosimilar, N297A Mutant | Catalog C006P.NA

Pertuzumab Biosimilar, N297A Mutant. Pertuzumab biosimilar CHO stable cell line is available for licensing to manufacture the pertuzumab biosimilar protein. The research grade pertuzumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available.

Product Specifications

Catalog No.	C006P.NA
Product Name	Pertuzumab Biosimilar, N297A Mutant
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Anti-ErbB-2 Humanized Monoclonal Antibody, Anti-c-neu Humanized Monoclonal Antibody
Summary	Recombinant humanized IgG1 monoclonal antibody.
Isotype	Human IgG1 N297A Mutant
Source/Host	Produced in the pertuzumab biosimilar CHO stable cell line.
Specificity	Specifically binds to the human HER2/ErbB-2/c-neu.

Properties & Storage

Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by pertuzumab.
Formulation	0.2 µM filtered solution, pH 6.0, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	Shipped with ice pack. Store immediately at recommended temperature.
Storage	12 months from receipt at -20 to -70°C; 1 month at 2 to 8°C. Avoid freeze-thaw cycles.

Background & Description

Pertuzumab, a humanized monoclonal antibody, inhibits HER dimerization and is used for the treatment of HER2-positive metastatic breast cancer, in combination with trastuzumab and docetaxel. By binding to HER2, Pertuzumab inhibits the dimerization of HER2 with other HER receptors, resulting in slowed tumor growth.